EP4098246A1 — Formulation of nintedanib
Assigned to Lotus Pharmaceutical Co Ltd · Expires 2022-12-07 · 3y expired
What this patent protects
The present invention relates to a formulation of nintedanib or a pharmaceutically acceptable salt thereof which contains a non-ionic surfactant. The formulation has an immediate release profile without the need to use lecithin as a surfactant. The formulation is suitable for fil…
USPTO Abstract
The present invention relates to a formulation of nintedanib or a pharmaceutically acceptable salt thereof which contains a non-ionic surfactant. The formulation has an immediate release profile without the need to use lecithin as a surfactant. The formulation is suitable for filling into capsules.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.